We have collaborations with world-class organizations and institutions at various stages of the R&D spectrum. Our clinical-stage partnerships focus on assessing optimal combinations of our drug candidates with other novel immuno-modulatory agents, as well as establishing the necessary safety and immunogenicity profiles of our clinical candidates. Our preclinical collaborations are aimed at generating supportive data to guide a potential future clinical path. We are also evaluating licensing opportunities with DPX-based therapeutic candidates in other hard-to-treat diseases.
IMV has multiple collaborations to evaluate its lead candidate, DPX-Survivac, with Merck’s checkpoint inhibitor, pembrolizumab.
Under this collaboration, IMV and The Wistar Institute partner to develop a targeted T cell therapy against the common BRAF cancer mutation, based on peptides identified by the Herlyn lab. Mutations in this gene are the most frequently identified cancer-causing mutations in melanoma and have been identified in various other cancers, including non-Hodgkin lymphoma, colorectal cancer, thyroid cancer, and non-small cell lung and ovarian carcinomas.The project scope includes optimizing the DPX formulation with the BRAF peptides and testing the investigational T cell therapy in the pioneering pre-clinical research models at Wistar. As part of the collaboration agreement, IMV holds an exclusive option to in-license intellectual property related to the program.